Elevated gamma-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 3, 2008, Pages 587-593

  Giral, Philippe ^a,b,c   Jacob, Nelly ^b   Dourmap, Caroline ^a,b   Hansel, Boris ^a,b,c   Carrié, Alain ^b,c   Bruckert, Eric ^a,b,c   Girerd, Xavier ^a,b   Chapman, M John ^c  

^a Service d'Endocrinologie métabolisme   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

glutamyltransferase; Cysteine; Glutathione; Metabolic syndrome; Oxidation

Indexed keywords

CYSTEINE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCINE; THIOL DERIVATIVE; BIOLOGICAL MARKER;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; BLOOD SAMPLING; COMPARATIVE STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUTATHIONE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; OXIDATION REDUCTION REACTION; PRIMARY PREVENTION; PRIORITY JOURNAL; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; BLOOD; BODY MASS; CROSS-SECTIONAL STUDY; ENZYMOLOGY; HOSPITALIZATION; INCIDENCE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX RATIO; STATISTICAL MODEL;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATION-REDUCTION; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SULFHYDRYL COMPOUNDS;

EID: 40749108557     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.157891     Document Type: Article

References (56)

1. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Vorarlberg Health Monitoring and Promotion Program Study. Group Gammaglutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-2137.
2. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27: 127-133.
3. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001; 38:263-355.
4. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489-492.
5. Shaw LM, Newman DA. Hydrolysis of glutathione by human liver gamma-glutamyltransferase. Clin Chem. 1979;25:75-79.
6. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE. European Concerted Action Project. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001;103:2544-2549.
7. Jacob N, Bruckert E, Giral P, Foglietti MJ, Turpin G. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999;146:53-59.
8. Bruckert E, Giral P, Ratziu V, Poynard T, Chapman MJ, Opolon P, Turpin G. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metabolism. 2002; 51:1071-1076.
9. Esposito K, Ciotola M, Schisano B, Misso L, Giannetti G, Ceriello A, Giugliano D. Oxidative stress in the metabolic syndrome. J Endocrinol Invest. 2006;29:791-795.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.Lancet. 2005;365:1415-1428.
11. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116:1813-1822.
12. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med. 2004;37: 1018-1023.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
14. Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti MJ, Turpin G. Homocysteine and lipid lowering agents. A comparison between Atorvastatin and Fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 2000;154:421-427.
15. Klauke R, Schmidt E, Lorentz K. Recommendations for carrying out standard ECCLS procedures. (1988) for the catalytic concentrations of creatine kinase, aspartate aminotransferase, alanine aminotransferase and gamma- glutamyltransferase at 37°. Eur J Clin Chem Clin Biochem. 1993; 31:901-909.
16. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27: 1213-1219.
17. Altman DG. Practical Statistics for Medical Research. Published in 1991 by Chapman and Hall.
18. Heistad DD. Oxidative stress and vascular disease: 2005 Duff lecture. Arterioscler Thromb Vasc Biol. 2006;26:689-695.
19. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421-429.
20. Onat A, Hergenc G, Karabulut A, Turkmen S, Dogan Y, Uyarel H, Can G, Sansoy V. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults. Prev Med. 2006;43:136-139.
21. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708.
22. Giral P, Ratziu V, Chapman J. Letter regarding article by Ruttmann et al, "γ-Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality: An Epidemiological Investigation in a Cohort of 163 944 Austrian Adults". Circulation 2006;113:e299.
23. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39: 754-763.
24. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol. 2006;44: 190-196.
25. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005;258:527-535.
26. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, Zinman B, Haffner SM. the Insulin Resistance Atherosclerosis Study: Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2004;53: 2623-2632.
27. Andre P, Balkau B, Born C, Charles MA. Eschwege E; D.E.S.I.R. study group. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006;49:2599-2603.
28. Van Gaal LF, Mertens interleukin (IL), De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444: 875-880.
29. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
30. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A.
31. Stocker R, Keaney JF. Role of Oxidative Modifications in Atherosclerosis. Physiol Rev. 2004;84:1381-1478.
32. Drozdz, R, Parmentier C, Hachad H, Leroy P, Siest G, Wellman M. g-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med. 1998;25: 786-792.
33. Paolicchi A, Minotti G, Tonarelli P, Tongiani R, De Cesare D, Mezzetti A, Dominici S, Comporti M, Pompella A. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation-a potential mechanism in atherosclerosis. J Investig Med. 1999;47:151-160.
34. Paolicchi A, Emdin M, Ghliozeni E, Ciancia E, Passino C, Popoff G, Pompella A. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation. 2004;109:1440-1441.
35. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta. 2003;333: 19-39.
36. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol. 2002;64: 1027-1035.
37. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR. Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation. 1999;100:2244-2247.
38. Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, Vaccarino V, Harrison DG, Quyyumi AA. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol. 2006;47:1005-1011.
39. Lapenna D, de Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calafiore AM, Napolitano AM, Di Ilio C, Cuccurullo F. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation. 1998;97: 1930-1934.
40. Jones DP, Go YM, Anderson CL, Ziegler TR, Kinkade JM Jr, Kirlin WG. Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control. FASEB J. 2004;18: 1246-1248.
41. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 1993;34:2051-2061.
42. Berliner JA, Watson AD. A role for oxidized phospholipids in athero-sclerosis.N Engl J Med. 2005;353:9-11.
43. Go YM, Jones DP. Intracellular proatherogenic events and cell adhesion modulated by extracellular thiol/disulfide redox state. Circulation. 2005; 111:2973-2980.
44. Nappi AJ, Vass E. Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochim Biophys Acta. 1997;1336:295-302.
45. Sakuta H, Suzuki T, Yasuda H, Ito T. Gamma-glutamyl transferase and metabolic risk factors for cardiovascular disease. Intern Med. 2005;44: 538-541.
46. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep. 2004;6:424-431.
47. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, Maruyama N, Kitagawa N, Tanaka T, Hori Y, Nakatani K, Yano Y, Adachi Y. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003;88:4673-4676.
48. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
49. Paolicchi A, Emdin M, Passino C, Lorenzini E, Titta F, Marchi S, Malvaldi G, Pompella A. Beta-lipoprotein- and LDL-associated serum gamma- glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186:80-85.
50. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53: 1068-1073.
51. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C. Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis. 2006;189: 369-374.
52. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ. Increased small lowdensity lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006; 113:20-29.
53. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89:4963-4971.
54. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42- 46.
55. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-1076.
56. Ginsberg HN, Zhang YL, Hernandez-Ono A Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006;14 Suppl 1:41S-49S.